Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ESS Tech Inc
NYSE:GWH
|
US |
|
A
|
Aallon Group Oyj
OMXH:AALLON
|
FI |
|
Ningbo Deye Technology Co Ltd
SSE:605117
|
CN |
|
OHB SE
XETRA:OHB
|
DE |
|
A
|
Alzinova AB
STO:ALZ
|
SE |
|
Jain Irrigation Systems Ltd
NSE:JISLJALEQS
|
IN |
Rigel Pharmaceuticals Inc
Total Current Liabilities
Rigel Pharmaceuticals Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
Total Current Liabilities
$99.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Rigel Pharmaceuticals Inc
Glance View
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
See Also
What is Rigel Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
99.2m
USD
Based on the financial report for Dec 31, 2025, Rigel Pharmaceuticals Inc's Total Current Liabilities amounts to 99.2m USD.
What is Rigel Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
11%
Over the last year, the Total Current Liabilities growth was 57%. The average annual Total Current Liabilities growth rates for Rigel Pharmaceuticals Inc have been 15% over the past three years , 19% over the past five years , and 11% over the past ten years .
